iifl-logo

Aarti Drugs Ltd Nine Monthly Results

471.15
(-0.67%)
Sep 5, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Dec-2024Dec-2023Dec-2022Dec-2021Dec-2020

Gross Sales

1,710.27

1,908.59

1,973.64

1,794.38

1,653.03

Excise Duty

0

0

0

0

0

Net Sales

1,710.27

1,908.59

1,973.64

1,794.38

1,653.03

Other Operating Income

0

0

0

0

0

Other Income

14.49

2.95

1.32

8.35

3.79

Total Income

1,724.76

1,911.54

1,974.96

1,802.73

1,656.82

Total Expenditure

1,516.53

1,677.93

1,761.58

1,550.93

1,296.86

PBIDT

208.23

233.61

213.38

251.8

359.96

Interest

26.71

24.39

24.66

14.84

18.59

PBDT

181.52

209.22

188.72

236.96

341.37

Depreciation

40.9

37.87

37.82

37.5

37.6

Minority Interest Before NP

0

0

0

0

0

Tax

30.81

44.46

39.97

50.92

77.44

Deferred Tax

4.48

2.61

0.75

-1.14

-2.42

Reported Profit After Tax

105.33

124.28

110.18

149.68

228.75

Minority Interest After NP

0.03

0.17

-0.04

-0.02

-0.01

Net Profit after Minority Interest

105.3

124.11

110.22

149.7

228.76

Extra-ordinary Items

0

0

0

0

0.17

Adjusted Profit After Extra-ordinary item

105.3

124.11

110.22

149.7

228.59

EPS (Unit Curr.)

11.54

13.47

11.9

16.14

24.54

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

10

0

10

10

0

Equity

91.27

91.94

92.6

92.6

93.2

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

12.17

12.23

10.81

14.03

21.77

PBDTM(%)

10.61

10.96

9.56

13.2

20.65

PATM(%)

6.15

6.51

5.58

8.34

13.83

Aarti Drugs: Related NEWS

Aarti Drugs Q3 Profit Up 1%, Revenue Drops 8% YoY

The consolidated net profit of the company increased 1.1% YoY at ₹37.1 crore from ₹36.7 crore that was reported for the same quarter last year.

30 Jan 2025|10:25 PM
Read More
Aarti Drugs Tarapur Facility Gets US FDA Clearance

Aarti Drugs shares has witnessed a 8% dip in the last one year, and 10% dip in the last six months.

26 Dec 2024|11:48 PM
Read More
Top 10 stocks for today - 4th October, 2024

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Bank of Baroda, HDFC Bank, etc.

4 Oct 2024|08:46 AM
Read More
Top 10 stocks for today – 23rd September 2024

Here are some of the stocks that may see significant price movement today: HFCL, Aster DM Healthcare, Tata Steel, Glenmark Pharma, etc.

23 Sep 2024|09:34 AM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.